anidulafungin has been researched along with 17-alpha-hydroxyprogesterone in 1 studies
| Studies (anidulafungin) | Trials (anidulafungin) | Recent Studies (post-2010) (anidulafungin) | Studies (17-alpha-hydroxyprogesterone) | Trials (17-alpha-hydroxyprogesterone) | Recent Studies (post-2010) (17-alpha-hydroxyprogesterone) |
|---|---|---|---|---|---|
| 568 | 33 | 331 | 2,148 | 145 | 434 |
| Protein | Taxonomy | anidulafungin (IC50) | 17-alpha-hydroxyprogesterone (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.051 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.051 | |
| Adenosine receptor A3 | Homo sapiens (human) | 4.73 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.3 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.739 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 4.73 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.051 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.051 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.051 | |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 3.157 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 4.73 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 6.905 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
1 other study(ies) available for anidulafungin and 17-alpha-hydroxyprogesterone
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |